EGFR and neoplasm: Similarly, in non-small cell lung cancer (NSCLC), tumor cells resistant to epidermal growth factor receptor (EGFR) inhibitors (erlotinib, osimertinib) depend heavily on the NRF2-mediated antioxidant response to maintain low intracellular ROS levels via upregulation of GPx4 and SOD2.